Biological Optionality: Why Freezing Your Younger Cells Now Is a Bet on Future Medicine
Acorn Biolabs harvests mesenchymal stem cells from hair follicles and cryopreserves them—banking the secretome of a healthier version of you against therapies that don't exist yet.
Alamar's Dried Blood Spot Kit Makes Hospital-Grade Proteomics Work on a Fingerstick at Home
Alamar Biosciences' NULISA DBS Extraction Kit extends proximity ligation proteomics to dried blood spot samples—85–95% detectability, compatible with Capitainer and Mitra devices, ships standard mail.
VERVE-102 and the Beginning of the End of Atherosclerosis
A Phase I trial published in the New England Journal of Medicine shows VERVE-102, a one-time base-editing gene therapy, can cut PCSK9 protein levels by up to 88% and LDL cholesterol by up to 62% — potentially permanently — in high-risk cardiovascular patients.
InsideTracker Pivots to AI Platform: What the Terra Shift Means for Biohacking
InsideTracker is becoming Terra, a B2B AI platform licensing biomarker-based health guidance to wellness and healthcare companies. The consumer brand isn't gone — it's becoming infrastructure.
Oura Ring 5: The Smallest Smart Ring Gets Serious About Health Data
Oura Ring 5 launches 40% smaller with a month-long charging case, blood pressure signal detection, and GLP-1 medication insights. What's genuinely new and who the upgrade makes sense for.
Plasma Exchange Cuts Blood Microplastics by 60%: First Clinical Data
A May 2026 study in the Journal of Clinical Apheresis found therapeutic plasma exchange reduced blood microplastic levels from 52.2 to 21.1 particles per 100µL — the first peer-reviewed data on clinically removing microplastics from circulation.
Elysium Health Launches Physician-Led Longevity Program — Moving From Supplements to Clinical Care
Elysium's new Elysium Longevity Institute combines NAD+ protocols, peptides, and longitudinal data tracking under physician oversight. The shift signals a broader move in longevity from consumer supplementation to integrated clinical programs.
Oura Ring 5: The World's Smallest Smart Ring Adds Blood Pressure Signals and GLP-1 Insights
Oura Ring 5 launches 40% smaller than its predecessor with rebuilt sensors, blood pressure monitoring signals, and a portable charging case. Here's what's new and who the upgrade makes sense for.
Sleep Pharmacology: Why Most Sleep Drugs Don't Deliver What You Think
Peter Attia's Episode 394 tackles which sleep medications actually work and which only sedate. The core insight — sedation is not sleep — reframes how to think about every drug in this category.
77% of Max Strength Gains With Light Weights Twice a Week
A meta-analysis of 192 studies finds that light-load, multi-set training twice a week captures 77% of maximal strength gains. The gap between optimal and accessible is far smaller than the fitness industry suggests.
resbiotic Makes Shotgun Metagenomics an At-Home Gut Test
resbiotic's at-home gut health test uses shotgun metagenomic sequencing — the same method clinical researchers use — with HSA/FSA eligibility and a 60-90 day retesting cadence built around lifestyle optimization.
Battery-Free Brain Implant Leaves the Lab: ABILITY Neurotech's ALS Trial
ABILITY Neurotech's optical-link BCI received approval for chronic home use in ALS patients — the first time this class of device moves from controlled demonstrations to real-world daily use.
Wearables: When Your Fitness Tracker Becomes a Medical Device
WHOOP's 2025 FDA warning revealed a hidden boundary inside wearables. As brands add clinical features, the wellness exemption is under pressure — and the implications run far beyond WHOOP.
Growth Hormone for Injury Recovery: The Evidence Gap Between Clinics and Clinical Trials
hGH reliably raises IGF-1. IGF-1 drives anabolic signaling. Somewhere between that mechanism and the recovery outcomes being sold in wellness clinics, the evidence breaks down.
Wearables Are Writing Checks the FDA Can't Cash: The Regulatory Gap Getting Harder to Ignore
WHOOP earned $34.5M in federal backing. Apple Watch won an ECG clearance. And the FDA's framework for governing what these devices claim is still built for episodic care, not continuous monitoring.
Scribe Therapeutics' STX-1150: Silencing PCSK9 Epigenetically Without Editing Your DNA
Scribe's STX-1150 cuts LDL 50%+ in primates for 18 months from a single dose — silencing PCSK9 epigenetically, not by altering the DNA sequence itself.
Peter Attia's Three-Question Framework for Cutting Through Supplement Noise
Peter Attia's AMA #85 framework for supplement evaluation: define the problem precisely, measure with a biomarker, and weigh risk against reward honestly.
Sunrise Air: What FDA Clearance for a Rechargeable Chin-Worn Sleep Test Actually Means
Sunrise Air's FDA clearance adds airflow sensors, O2 monitoring, and a rechargeable design to mandibular jaw tracking. What changes for home sleep diagnostics.
Biohacking's Biggest Surprise: The Average Practitioner Is Over 65
The largest age group in biohacking is 65+, most practitioners spend under $500/month, and strength training beats peptide therapy 2:1.
Glycans: The Aging Biomarker That Predicts Disease a Decade Early
IgG glycans explain 58% of age variance—more than telomeres—and predict cardiovascular events and diabetes onset up to 10 years early. Here's what that means.
Ossium Health: The Case for Rebuilding the Immune System From Scratch
PRESERVE I trial: all 4 patients achieved full donor chimerism and remained relapse-free at Day 180 using banked deceased-donor bone marrow. What this means for longevity.
Diathrive + KardiaComplete: The Cardiometabolic Stack Getting FDA-Grade ECG Into Diabetes Care
People with Type 2 diabetes face 2-3x higher AFib risk, yet most digital health platforms treat heart and glucose monitoring separately. The Diathrive-KardiaComplete integration changes that.
Fasting as Regenerative Medicine: What the FMD Data Actually Shows
Dr. Valter Longo's clinical trials show fasting-mimicking cycles reduce biological age by 2.5 years and helped 60-70% of diabetes patients reduce medications. The mechanism isn't weight loss.
4 Genetic Tests Worth Getting — And Why Most Aren't
Peter Attia's Episode #392 framework on genetic testing: the four high-penetrance tests that actually change clinical decisions, and why most DTC tests don't.